XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...
The probability of survival at 8 years was an unprecedented 78.9% with XTANDI plus leuprolide versus 69.5% with leuprolide, in men with non-metastatic hormone-sensitive prostate cancer with high-risk ...
(RTTNews) - Pfizer Inc. (PFE) and Astellas Pharma U.S. Inc. announced final overall survival results from the Phase 3 EMBARK study evaluating XTANDI (enzalutamide), in combination with leuprolide and ...
What criteria do clinicians use to classify men as “high risk” among patients with biochemically recurrent nonmetastatic castration-sensitive prostate cancer? This is an ASCO Meeting Abstract from the ...
Differences in Patient-Reported Outcome Measures in Patients With Cancer Six Months Before Death All premenopausal patients who underwent first HSCT from June 2016 to January 2022 were included in ...
ADT-associated cardiovascular risk may be partly mediated by accelerated coronary atherosclerosis. Plaque progression is more pronounced with the GnRH agonist leuprolide compared with the GnRH ...
Based on EMBARK data, both enzalutamide monotherapy and combination therapy (with leuprolide) reduced the likelihood of distant metastasis in patients with high-risk biochemically recurrent prostate ...
LUPRON DEPOT-3 MONTH 11.25mg prescription and dosage sizes information for physicians and healthcare professionals. Pharmacology, adverse reactions, warnings and side effects.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results